Big Pharma’s China Deal Wave & 12 Companies on Our Radar
A snap look at some of the deal dynamics and company platforms pulling global pharma toward China.
In late January, AstraZeneca announced a $15B investment in China through 2030, expanding R&D on Chinese soil with more manufacturing, and a focus on cell therapies and radioconjugates. The expansion builds on AstraZeneca’s long-running China footprint, which began in 1993 and currently runs two R&D centers in Shanghai and Beijing.
In this issue: From Generics to Innovation — Five Growth Stats — Company Radar — Rise & Constraints
To read the rest of this article, upgrade to a BiopharmaTrend Pro subscription.
Gain full access to all of our deep dives and content archives.
Already a member? Sign in here.
